CN113350531A - Prostate specific membrane antigen binding ligand conjugate and application thereof - Google Patents
Prostate specific membrane antigen binding ligand conjugate and application thereof Download PDFInfo
- Publication number
- CN113350531A CN113350531A CN202010141697.XA CN202010141697A CN113350531A CN 113350531 A CN113350531 A CN 113350531A CN 202010141697 A CN202010141697 A CN 202010141697A CN 113350531 A CN113350531 A CN 113350531A
- Authority
- CN
- China
- Prior art keywords
- conjugate
- group
- formula
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title claims abstract description 32
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title claims abstract description 32
- 239000003446 ligand Substances 0.000 title claims abstract description 17
- 230000027455 binding Effects 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 9
- 239000012216 imaging agent Substances 0.000 claims abstract description 3
- 125000005647 linker group Chemical group 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 239000013522 chelant Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 230000003439 radiotherapeutic effect Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910018830 PO3H Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- -1 L-form amino acids Chemical class 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000004255 ion exchange chromatography Methods 0.000 description 7
- 238000002603 single-photon emission computed tomography Methods 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000110 microvilli Anatomy 0.000 description 4
- 231100000417 nephrotoxicity Toxicity 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 206010029155 Nephropathy toxic Diseases 0.000 description 3
- 210000001099 axilla Anatomy 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007694 nephrotoxicity Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 2
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QJUIUFGOTBRHKP-LQJZCPKCSA-N (2s)-2-[[(1s)-1-carboxy-5-[6-[3-[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]methyl]-4-hydroxyphenyl]propanoylamino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC=2C(=CC=C(CCC(O)=O)C=2)O)CC(O)=O)=C1 QJUIUFGOTBRHKP-LQJZCPKCSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical group C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 108090000007 Carboxypeptidase M Proteins 0.000 description 1
- 102100032936 Carboxypeptidase M Human genes 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010037516 PSMA-617 Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GFABNNMTRVBLPZ-QRPNPIFTSA-N azanium;5-[[(4s)-4-amino-4-carboxybutanoyl]amino]-2-nitrobenzoate Chemical compound N.OC(=O)[C@@H](N)CCC(=O)NC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 GFABNNMTRVBLPZ-QRPNPIFTSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- NTUGPDFKMVHCCJ-UHFFFAOYSA-N ditert-butyl 2-aminopentanedioate Chemical compound CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C NTUGPDFKMVHCCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- JBHPLHATEXGMQR-LFWIOBPJSA-N vipivotide tetraxetan Chemical compound OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC=C2C=CC=CC2=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O JBHPLHATEXGMQR-LFWIOBPJSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to prostate specific membrane antigen binding ligand conjugates and uses thereof. In particular to a conjugate shown as a formula I, a labeled compound comprising the conjugate, and application of the conjugate as an imaging agent and a therapeutic drug for diagnosing and treating prostate cancer.
Description
Technical Field
The invention belongs to the field of medicine, and particularly relates to a prostate specific membrane antigen binding ligand conjugate and application thereof.
Background
Prostate cancer (Pca) is one of the most prominent cancers, with over one million men diagnosed each year. Conventional treatments for cancer include surgery, radiation, chemotherapy, and hormone therapy, however, effective treatments for recurrent, metastatic, and hormone therapy-independent prostate cancer are still lacking.
Prostate Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein with abundant but specific expression on the surface of prostate cancer, especially in androgen-independent, advanced and metastatic disease. Another advantage of PSMA as a target for nuclear medicine is that it has a relatively large extracellular domain. A variety of PSMA-targeted radiotracers and radiopharmaceutical therapies have entered clinical trials for clinical diagnostic imaging and treatment of metastatic castration resistant prostate cancer (mCRPC).
PSMA-11 Adaptation68Ga is currently the most effective ligand for PSMA-targeted imaging, and other ligands, including PSMA-617 and PSMA-I&T-match177Lu,213Bi or225Ac, also showed good results in PSMA-targeted therapy. Despite the excellent in vivo properties of radiolabeled PSMA ligands in clinical diagnostic imaging, therapeutic PSMA ligands currently have a very short biological half-life, high nephrotoxicity, very low complete remission rates in the clinic, and 30% of patients have disease progression after treatment.
In view of the above, there is an urgent need in the art to develop novel PSMA ligands that are more potent, have lower nephrotoxicity, and have a longer biological half-life.
Disclosure of Invention
The invention aims to provide a conjugate formed by coupling different connecting groups, chelates and PSMA binding ligands, wherein the conjugate can selectively target cancer cells, improve the in vivo distribution of drugs and reduce the toxicity risk, and provides a safer new choice for PSMA targeted radiopharmaceutical therapy.
In a first aspect of the invention, a conjugate is provided, wherein the conjugate is represented by formula I
Y1-L1-Z1(I)
Wherein,
(i) y1 is a chelate moiety;
(ii) z1 is a PSMA-binding ligand moiety represented by formula III;
wherein R is1Each independently selected from the group consisting of: -COOH, -SO2H、-CO3H、-CO4H、-PO2H、-PO3H. and-PO4H2(ii) a And
(iii) l1 is a linker for linking the Z1 and the Y1, and the linking group is covalently linked to the Y1 and the Z1; and is
L1 is composed of two or more structural units selected from the group consisting of:
r is selected from the group consisting of: substituted or unsubstituted-C1-C4 alkylene-C6-C10 aryl, substituted or unsubstituted-C1-C4 alkylene-5 to 10 membered heteroaryl; wherein the heteroaryl group contains 1 to 5 (preferably 1, 2 or 3) heteroatoms selected from O, S and N; by substituted is meant that one or more (preferably, 1, 2 or 3) hydrogens in the group are replaced with a substituent selected from the group consisting of: C1-C4 alkyl, phenyl substituted with one or more (preferably, 1, 2 or 3) C1-C4 alkyl;
l2 is unsubstituted or substituted by one or more (preferably, 1, 2 or 3) R2Substituted C1 to C8 alkylene;
R2each independently selected from the group consisting of: C1-C4 alkyl, -COOH, -C (O) N (R)3)2-COO-C1-C4 alkyl; and
R3selected from the group consisting of: H. C1-C4 alkyl.
In another preferred embodiment, the amino acid residue is derived from a natural amino acid or a non-natural amino acid.
In another preferred embodiment, the amino acid residues are derived from D-and/or L-form amino acids.
In another preferred embodiment, the amino acid residues are derived from D-and/or L-form amino acids.
In another preferred embodiment, the amino acid residue is a residue derived from an amino acid selected from the group consisting of: ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly (G), His (H), Ile (I), Leu (L), Lys (K), Met (M), Phe (F), Pro (P), Ser (S), Thr (T), Trp (W), Tyr (Y) and Val (V);
in another preferred embodiment, the amino acid residue is-NH-CH (R)a) -CO-, and RaSelected from: H. C1-C6 alkyl (preferably, - (CH)2)3-CH3、-CH(CH3)2) C1-C4 alkylene-S-C1-C4 alkyl (preferably, - (CH)2)2-S-CH3) C1-C4 alkylene-O-C1-C4 alkyl.
In another preferred embodiment, R is selected from the group consisting of: substituted or unsubstituted- (CH)2) -C6-C10 aryl, substituted or unsubstituted- (CH)2) -a 5 to 10 membered heteroaryl.
in another preferred embodiment, at least one structural unit of L1 isL1 has only one structural unit of
In another preferred embodiment, at least one structural unit of L1 isL1 has only one structural unit of
In another preferred embodiment, L1 is a linking group as shown in formula IV;
-(A1)n1-Aa-(A2)n2-Ab-(A3)n3-*(IV)
wherein,
denotes the end connected to Z1;
A1、A2And A3Each independently is a structural unit selected from the group consisting of:
amino acid residue, -NR3-L2-NR3-、-NR3-L2-CO-, C1-C8 alkylene;
l2, R and R3As previously defined;
n1, n2 and n3 are each independently an integer of 0 to 20; and n1, n2 and n3 are not 0 at the same time.
In another preferred example, n2 is 0.
In another preferred example, n3 is 0.
In another preferred example, n1 is 1,3, 4, 5, 6, 7, 8, 9 or 10.
In another preferred embodiment, L1 is a linking group according to formula IVa;
-(A1)n1-Aa-Ab-* (IVa)
In another preferred embodiment, L1 is a linking group according to formula IVb,
wherein denotes one end connected to Z1;
L3as defined by L2;
A4is an amino acid residue or-NR3-L2-CO-; and n4 is 0, 1, 2, 3, 4, 5, 6, or 7.
In another preferred embodiment, A4Are amino acid residues.
In another preferred embodiment, A4is-NH-CH (R)a) -CO-; wherein R isaSelected from: H. C1-C6 alkyl (preferably, - (CH)2)3-CH3、-CH(CH3)2) C1-C4 alkylene-S-C1-C4 alkyl (preferably, - (CH)2)2-S-CH3) C1-C4 alkylene-O-C1-C4 alkyl.
In another preferred embodiment, L1 is a linking group according to formula IVc:
in another preferred embodiment, L1 is the corresponding linking group in the compounds of table a, table B1, table B2, table C1 and table C2.
In another preferred embodiment, Y1 is a monovalent radical derived from DOTAGA.
In another preferred embodiment, Y1 is represented by formula II;
in another preferred embodiment, Z1 is represented by formula IIIa;
in another preferred embodiment, Z1 is according to formula IIIb,
in another preferred embodiment, the conjugate is selected from table a, table B1, table B2, table C1 and table C2.
In a second aspect of the invention there is provided the use of a compound as described in the first aspect in the preparation of a labelled compound.
In another preferred embodiment, the marker compound is for use in vivo imaging or in vivo radiotherapy in a subject, for diagnosing or treating prostate cancer and/or metastases thereof.
In a third aspect of the invention there is provided a labelled compound wherein the labelled compound comprises a conjugate as described in the first aspect and a label attached to or associated with or complexed or chelated with the conjugate.
In another preferred embodiment, the label is a detectable label.
In another preferred embodiment, the label is an isotope.
In another preferred embodiment, the isotope is selected from the group consisting of: a diagnostic isotope, a therapeutic isotope, or a combination thereof.
In another preferred embodiment, the diagnostic isotope is selected from the group consisting of: tc-99m, Ga-68, F-18, I-123, I-125, I-131, In-111, Ga-67, Cu-64, Zr-89, C-11, Lu-177, Re-188, or combinations thereof.
In another preferred embodiment, the therapeutic isotope is selected from the group consisting of: lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd-103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Xe-133Yb-169, Yb-177, or a combination thereof.
In another preferred embodiment, the label is attached to or associated with or complexed or chelated to the moiety Y1 of the conjugate of formula I.
In another preferred embodiment, the label is attached to or associated with or complexed or chelated with the moiety Y1 of the conjugate of formula I to form a structure according to formula V;
wherein M represents a label.
In a fourth aspect of the invention there is provided a composition comprising a conjugate according to the first aspect or a labelled compound according to the third aspect.
In another preferred embodiment, the composition further comprises a pharmaceutically acceptable carrier.
In a fifth aspect of the invention there is provided the use of a conjugate according to the first aspect or a labelled compound according to the third aspect in the preparation of an imaging agent and/or a radiotherapeutic and/or diagnostic agent.
In a sixth aspect of the invention there is provided the use of a conjugate according to the first aspect or a labelled compound according to the third aspect in the manufacture of a medicament for the diagnosis and/or treatment of prostate cancer and/or metastases thereof.
In another preferred embodiment, the diagnosis comprises staging and screening of appropriate patients for targeted delivery of the treatment.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Drawings
FIG. 1A shows the structure of Compound 1 (top panel) and its RP-HPLC and ion chromatography detection results (bottom panel).
FIG. 1B shows the structure of Compound 2 (top panel) and its RP-HPLC and ion chromatography detection results (bottom panel).
FIG. 1C shows the structure of Compound 3 (top panel) and its RP-HPLC and ion chromatography detection results (bottom panel).
FIG. 1D shows the structure of Compound 4 (top panel) and its RP-HPLC and ion chromatography detection results (bottom panel).
FIG. 1E shows the structure of Compound 5 (top panel) and its RP-HPLC and ion chromatography detection results (bottom panel).
Detailed Description
The inventors have conducted extensive and intensive studies. The conjugate with a novel structure shown in a formula I is developed for the first time. The special structure of the conjugate (especially the connecting group connecting the PSMA binding ligand and the chelate) enables the conjugate to have lower nephrotoxicity, longer biological half-life, excellent in vivo blood circulation, low renal radiation dose, higher tumor radiation accumulation and absorption and excellent tumor growth inhibition capability compared with the existing PSMA binding ligand conjugate. Based on this, the inventors have completed the present invention.
Term(s) for
As used herein, "C1-C6 alkyl" refers to a straight or branched chain alkyl group including 1-6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, or the like.
As used herein, "C1-C6 alkoxy" includes straight or branched chain alkoxy groups of 1-6 carbon atoms. Such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, or the like.
Unless otherwise indicated, the term "aryl" denotes a polyunsaturated (usually aromatic) hydrocarbon group which may be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The term "heteroaryl" refers to an aryl (or ring) containing 1 to 5 heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom is optionally quaternized. The heteroaryl group may be attached to the rest of the molecule through a heteroatom. Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl groups, while non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuranyl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridyl, thienopyrimidyl, pyrazolopyrimidinyl, imidazopyridine, benzothiazolyl, benzofuranyl, benzothienyl, indolyl, quinolinyl, isoquinolinyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furanyl, thienyl, and the like. The substituents for each of the above aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
The term "alkylene" by itself or as part of another substituent refers to a divalent radical derived from an alkane, e.g., -CH2CH2CH2CH2-。
Unless otherwise defined, amino acids herein include natural amino acids or unnatural amino acids, including D-and/or L-form amino acids. Examples of amino acids include, but are not limited to, Ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly (G), His (H), Ile (I), Leu (L), Lys (K), Met (M), Phe (F), Pro (P), Ser (S), Thr (T), Trp (W), Tyr (Y), Val (V). Preferably, herein, the amino acid is an amino acid selected from the group consisting of: l-glycine (L-Gly), L-alanine (L-Ala), beta-alanine (beta-Ala), L-glutamic acid (L-Glu), L-aspartic acid (L-Asp), L-histidine (L-His), L-arginine (L-Arg), L-lysine (L-Lys), L-valine (L-Val), L-serine (L-Ser), L-threonine (L-Thr).
As used herein, the term "amino acid residue" refers to the N-terminal-NH-of an amino acid2Removing one H, and removing a group formed by-OH from-COOH at the C terminal. The amino acid residues may be derived from natural amino acids or non-natural amino acids, and may be derived from residues of D-and/or L-amino acids.
As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), and silicon (Si).
Unless otherwise specified, all occurrences of a compound in the present invention are intended to include all possible optical isomers, such as a single chiral compound, or a mixture of various chiral compounds (i.e., a racemate). In all compounds of the present invention, each chiral carbon atom may optionally be in the R configuration or the S configuration, or a mixture of the R configuration and the S configuration.
As used herein, renal brush border enzymes (renal brush border enzymes) refer to a group of enzymes that bind to the brush border of the microvillous membrane (microvillous membrane) including, but not limited to: alkaline phosphatase (ALP), Leucine Aminopeptidase (LAP), γ -glutamyltransferase (y-GT), and carboxypeptidase M.
Conjugates
The invention provides a PSMA radioligand conjugate with a novel structure, which is modified aiming at the PSMA radioligand, so that the conjugate can be used as an albumin adhesive to bind albumin (albumin) so as to improve the half-life of the conjugate. In addition, the conjugate is modified with a kidney brush border enzyme cleavable linking group (linker) so that the conjugate can be degraded in the kidney and thus has lower renal toxicity. Therefore, the conjugate with the novel structure provided by the invention effectively enhances the in vivo blood circulation of the PSMA radioligand and reduces the kidney radiation dose, has positive influence on the overall motion characteristic of the medicament, increases the tumor radioactive accumulation and improves the treatment effect.
In one embodiment, the invention provides a conjugate as shown in formula I;
Y1-L1-Z1 (I)
wherein Y1, L1 and Z1 are as defined in the first aspect.
In another embodiment, L1 may also be a linking group selected from the group consisting of:
in another particularly preferred embodiment, L1 may also be a linking group selected from the group consisting of:
in another embodiment, the conjugate is selected from table a
TABLE A
In another specific embodiment, the conjugate is selected from table B1 and table B2
TABLE B1
TABLE B2
In another specific embodiment, the conjugate is selected from table C1 and table C2:
TABLE C1
TABLE C2
Preparation method
The conjugates or labeled compounds of the invention can be prepared by conventional methods from suitable starting materials or according to the methods disclosed in the specific examples.
Imaging or radiotherapeutic agents
The conjugates according to the invention (formula I) are used as radioimaging agents or also as radiotherapeutic agents (drugs) or diagnostic agents, complexing, chelating different isotopes, such as radioisotopes, to the chelate moiety. Exemplary isotopes include, for example: tc-99m, Ga-68, F-18, I-123, I-125, I-131, In-111, Ga-67, Cu-64, Zr-89, C-11, Lu-177, Re-188, Lu-177, Y-90, Ac-225, As-211, Bi-212, Bi-213, Cs-137, Cr-51, Co-60, Dy-165, Er-169, Fm-255, Au-198, Ho-166, I-125, I-131, Ir-192, Fe-59, Pb-212, Mo-99, Pd-103, P-32, K-42, Re-186, Re-188, Sm-153, Ra223, Ru-106, Na24, Sr89, Tb-149, Th-227, Pd-227, Mo-103, Mo-32, Cu-87, Cu-56, Mo-K-87, Cu-56, Mo-227, Cu-III, Cu, Xe-133Yb-169 and Yb-177.
Pharmaceutical compositions and methods of administration
As used herein, the term "compound of the invention" or "conjugate of the invention" refers to a compound or conjugate of formula I.
Since the conjugate of the present invention has an excellent binding ability to Prostate Specific Membrane Antigen (PSMA), the conjugate or the compound or the labeled compound, a pharmaceutically acceptable inorganic or organic salt, hydrate or solvate, and a composition containing the compound as a main active ingredient can be used for the treatment, prevention and diagnosis of prostate cancer and related diseases such as metastasis thereof.
The composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof in a safe and effective amount range and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-500mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and with the compounds of the present invention without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g. soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (e.g. vomit-ethanol, sodium lauryl sulfate, sodium chloride, sodium lauryl sulfate, sodium chloride, sodium lauryl sulfate, sodium chloride, sodium lauryl sulfate, sodium chloride, sodium) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms for topical administration of the compounds of the present invention include ointments, powders, patches, sprays, and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if necessary.
The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) to be treated, wherein the administration dose is a pharmaceutically-considered effective administration dose, and for a human body with a weight of 60kg, the daily administration dose is usually 1 to 2000mg, preferably 20 to 500 mg. Of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.
The main advantages of the invention include:
a) different linkers are used to create a new small molecular structure, and compared with the existing similar PSMA radioactive ligand, the kidney radiation dose and toxicity are reduced.
b) The chelate uses DOTAGA, and the PSMA binding ligand-linker-chelate commonly used at present mainly uses DOTA which can more effectively and stably connect the radioactive isotope
c) The conjugate can be used as a binding albumin adhesive, so that the in vivo blood circulation of the PSMA radioligand can be effectively enhanced, the overall motion characteristic of the medicine is positively influenced, the radioactive accumulation of the tumor is increased, and the treatment effect is improved.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
Example 1: synthesis of DOTAGA-coupled ligands
The DOTAGA-linked PSMA ligand was synthesized by solid phase peptide synthesis.
In the first step, by drying CH in 200ml at 5 ℃ for 3h2Cl23mmol of bis (tert-butyl) -L-glutamate and 3ml of N-ethyldiisopropylamine (DIPEA) in (1) was added to 10ml of dry CH2Cl2In situ formation of glutamyl-partial isocyanates in a solution of 1mmol of triphosgene, addition of 0.5mmol of resin-immobilized (2-chloro-trityl resin) E-allyloxycarbonyl-protected lysine after the reaction and reaction under gentle stirring for 16h, filtration of the resin and use of 4ml of CH2Cl250mg of tetrakis (triphenyl) palladium and 400. mu.l of morpholine removed the allyloxy protecting group in 2 h.
The subsequent synthesis of the peptidomimetic PSMA binding motif was performed according to the standard Fmoc procedure, ligation of linker moieties was performed using 2mmol of the corresponding Fmoc protected acid, 3.96nmol of HBTU and 2mmol of N-ethyl-diisopropylamine in a final volume of 4ml of DMF, and after 1h of activation with 3.95eq of HBTU and DIPEA, 4eq of DODAGA-NHS relative to the resin load was reacted in a final volume of 3ml of DMF. The product was resin sheared from 2ml of a mixture consisting of trifluoroacetic acid, triisopropylsilane, and water (95:2.5:2.5) and purified using RP-HPLC to obtain the compounds shown in table a.
The purity and TFA (trifluoroacetic acid) content of the synthesized compounds were determined using RP-HPLC and ion chromatography, respectively (see FIGS. 1A-1E for RP-HPLC and ion chromatography results), while the compounds were identified using high resolution mass spectrometry. The quality control data for the compounds are shown in table 1.
Table 1 quality control data for compounds
Exterior surface | Molecular weight | Purity of | | |
Compound | ||||
1 | White powder | 1273Da | >99% | 12.4% |
Compound 2 | White powder | 1461Da | >98% | 10.1% |
Compound 3 | White powder | 1605Da | >97% | 8.2% |
Compound 4 | White powder | 1475Da | >98% | 9.3% |
Compound 5 | Yellow powder | 1325Da | >97% | 0.7% |
Example 2:177lu radiolabeling and stability assays
1nmol of the compounds 1 to 5 synthesized in example 1 and PSMA-I&T (from Scitomics GmbH) were dissolved in 100. mu.l of 0.5M sodium acetate solution pH8.0, 10. mu.l of 2M sodium acetate solution pH8.0 and 40. mu.l of177LuCl3Adjusting the pH of the labeling solution to 4 in a mixture of eluents (50MBq), reacting at 95 ℃ for 45min, and subjecting to RP-HPLC and thin layer chromatography177The Lu labeled compound is subjected to quality control, thereby obtaining77Lu labeling compound.
In addition, 30. mu.l of the extract was taken177Lu labeling compound, adding 300. mu.l phosphate buffer or human serum, and incubating at 37 ℃ for 1, 6 and 24 h. Using RP-HPLC and thin layer chromatography177The Lu labelled compound stability was analyzed.177The radiochemical purity and stability data for the Lu-labelled compounds are shown in the table2。
The results show that the invention177The radiochemical purity of the Lu labeled compound reaches more than 95 percent, and the Lu labeled compound is not degraded in 24 hours of in vitro serum incubation and is very stable.
TABLE 277Radiochemical purity and stability data for Lu-labelled Compounds
Example 3 in vitro PSMA binding assay
Inoculating 5X 10 axilla on the right side of Balb/c nude mice5A PSMA high expression (LNCaP C4.2) cell, when the tumor grows to 100-3Tumors were excised, frozen sections of 5mm thickness were prepared and adhered to slides. The slides were placed in protein solution, incubated at room temperature for 20min for pre-blocking, transferred to 40ml of phosphate buffer containing 0.5% bovine serum albumin, and 0.2nM of the solution prepared in example 2 was added177Lu labeled compound, or the compound of example 1 added simultaneously at 0.04, 0.2, 1, 5 and 25nM, incubated for 1h at room temperature, then the slides were washed 4 times with ice cold buffer for 3min each, air dried at room temperature and mounted on a phosphorescent imaging plate and exposed for 15 min. Scanning the slide with a bioimaging analyzer and calculating using image analysis software177Affinity of Lu-tagged compounds to PSMA. The results show that the invention177The affinity of the Lu-labeled compound for PSMA reached above the nM level and was determined to be specific binding.
Example 4: SPECT imaging study
Inoculating 5X 10 axilla on the right side of Balb/c nude mice5A PSMA high expression (LNCaP C4.2) cell, when the tumor grows to 300-3Used for formal experimental study.
Tumor-bearing mice were anesthetized by isoflurane and the tail vein was injected with the drug of example 2177Lu labeled compound (. about.1 nmol,40 MBq). Scanning is carried out 2, 24 and 72 hours after the administration, and the collection mode is static SPECT for 30min and medium-resolution whole body CT. Performing a transabdominal dissection, weighing and measuring radioactivity using a gamma counter after completion of a SPECT/CT scanAnd calculating ID/g, formalin-fixed organ and use as H&And E, dyeing.
From the 72h SPECT/CT scan pictures and the in-vivo distribution data obtained, it can be seen that the invention177Lu-labelled Compounds comparison with PSMA-I&T can effectively enhance the blood circulation in vivo and reduce the radiation dose of the kidney, increases the radioactive accumulation and absorption of the tumor, and has positive influence on the overall motion characteristic of the medicine.
Example 5 therapeutic Effect study
Inoculating 5X 10 axilla on the right side of Balb/c nude mice5A PSMA high expression (LNCaP C4.2) cell, when the tumor grows to 100-3Used for formal experimental study.
Tail vein injection of example 2177Lu labeled compound (. about.2 nmol,60 MBq). Mice were monitored daily for behavior and survival, and weekly for 2 body weights and tumor growth. SPECT/CT scanning is carried out 72h after administration, and the acquisition mode is static 30min SPECT and medium resolution whole body CT. Organ dissection was performed 8 weeks after drug administration, and formalin-fixed organs were used as H&And E, dyeing.
According to the obtained part177The SPECT/CT scanning picture and the tumor growth data of the Lu labeled compound in a tumor bearing mouse for 72h can be seen177Lu-labeled Compound comparison PSMA-I&The T can more effectively inhibit the tumor growth of the tumor-bearing mice and improve the survival rate, and meanwhile, the body weight of the tumor-bearing mice is kept unchanged or increased in the survival period and has no obvious toxic signs.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (10)
1. A conjugate, wherein the conjugate is represented by formula I
Y1-L1-Z1 (I)
Wherein,
(i) y1 is a chelate moiety;
(ii) z1 is a PSMA-binding ligand moiety represented by formula III;
wherein R is1Each independently selected from the group consisting of: -COOH, -SO2H、-CO3H、-CO4H、-PO2H、-PO3H. and-PO4H2(ii) a And
(iii) l1 is a linking group for linking the Z1 and the Y1, and the linking group is covalently linked to the Y1 and the Z1; and is
L1 is composed of two or more structural units selected from the group consisting of:
r is selected from the group consisting of: substituted or unsubstituted-C1-C4 alkylene-C6-C10 aryl, substituted or unsubstituted-C1-C4 alkylene-5 to 10 membered heteroaryl; wherein the heteroaryl group contains 1 to 5 heteroatoms selected from O, S and N; by substituted is meant that one or more hydrogens of the group are replaced with a substituent selected from the group consisting of: C1-C4 alkyl, phenyl substituted with one or more C1-C4 alkyl groups;
l2 is unsubstituted or substituted by one or more R2Substituted C1 to C8 alkylene;
R2each independently selected from the group consisting of: C1-C4 alkyl, -COOH, -C (O) N (R)3)2-COO-C1-C4 alkyl; and
R3selected from the group consisting of: H. C1-C4 alkyl.
2. The conjugate of claim 1, wherein L1 is a linking group according to formula IV;
-(A1)n1-Aa-(A2)n2-Ab-(A3)n3-* (IV)
wherein,
denotes the end connected to Z1;
A1、A2And A3Each independently is a structural unit selected from the group consisting of:
amino acid residue, -NR3-L2-NR3-、-NR3-L2-CO-, C1-C8 alkylene;
l2, R and R3As previously defined;
n1, n2 and n3 are each independently an integer of 0 to 20; and n1, n2 and n3 are not 0 at the same time.
6. Use of a compound according to claim 1 for the preparation of a labeled compound.
7. A labelled compound comprising the conjugate of claim 1 and a label attached or associated or complexed or chelated thereto.
8. A composition comprising the conjugate of claim 1 or the labeled compound of claim 7.
9. Use of a conjugate according to claim 1 or a labelled compound according to claim 7 in the preparation of an imaging agent and/or a radiotherapeutic and/or diagnostic agent.
10. Use of a conjugate according to claim 1 or a labelled compound according to claim 7 in the manufacture of a medicament for the diagnosis and/or treatment of prostate cancer and/or metastases thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010141697.XA CN113350531A (en) | 2020-03-02 | 2020-03-02 | Prostate specific membrane antigen binding ligand conjugate and application thereof |
PCT/CN2021/077858 WO2021175147A1 (en) | 2020-03-02 | 2021-02-25 | Prostate-specific membrane antigen-binding ligand conjugate and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010141697.XA CN113350531A (en) | 2020-03-02 | 2020-03-02 | Prostate specific membrane antigen binding ligand conjugate and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113350531A true CN113350531A (en) | 2021-09-07 |
Family
ID=77523212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010141697.XA Pending CN113350531A (en) | 2020-03-02 | 2020-03-02 | Prostate specific membrane antigen binding ligand conjugate and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113350531A (en) |
WO (1) | WO2021175147A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104610431B (en) * | 2014-11-26 | 2017-12-15 | 南京市第一医院 | A kind of polypeptide and its application |
CN110740757B (en) * | 2017-05-24 | 2023-04-04 | 同位素技术慕尼黑公司 | Novel PSMA-binding agents and uses thereof |
CA3071315A1 (en) * | 2017-07-28 | 2019-01-31 | Technische Universitat Munchen | Dual mode radiotracer and -therapeutics |
DE102018126558A1 (en) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Marking precursor with square acid coupling |
-
2020
- 2020-03-02 CN CN202010141697.XA patent/CN113350531A/en active Pending
-
2021
- 2021-02-25 WO PCT/CN2021/077858 patent/WO2021175147A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2021175147A1 (en) | 2021-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210283279A1 (en) | Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancer | |
EP0772628B1 (en) | Peptide derived radionuclide chelators | |
EP0329481A2 (en) | Anchimeric radiometal chelating compounds | |
JP4236282B2 (en) | Radiolabeled peptide composition for site-specific targeting | |
JPH09500140A (en) | Hydrazino-type radionuclide chelating agent having N configuration 3 S configuration | |
JP2014503546A (en) | Radiolabeled HER2 binding peptide | |
JP2000515514A (en) | Analogous compounds of radiometal element binding peptides | |
EP3209336A1 (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
WO1995017419A1 (en) | Metal chelators | |
US8575100B2 (en) | Tc and Re labeled radioactive glycosylated octreotide derivatives | |
WO2021175147A1 (en) | Prostate-specific membrane antigen-binding ligand conjugate and application thereof | |
US11426395B2 (en) | PSMA inhibitor derivatives for labelling with 99mTc via HYNIC, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics | |
US6995247B2 (en) | Ac-HEHA and related compounds, methods of synthesis and methods of use | |
Kothari et al. | 99mTc (CO) 3-VIP analogues: preparation and evaluation as tumor imaging agent | |
Zhang et al. | In vitro and in vivo evaluation of [99mTc (CO) 3]-radiolabeled ErbB-2-targeting peptides for breast carcinoma imaging | |
JP2005047821A (en) | Diagnostic or therapeutic medicine using cyclopentadienyl carbonyl group-containing radiactive compound | |
WO2024051794A1 (en) | Radionuclide-drug conjugate and pharmaceutical composition and use thereof | |
CN117120428A (en) | Truncated Evan blue modified fibroblast activation protein inhibitor and preparation method and application thereof | |
JPH11505852A (en) | Isolated diagnostic imaging agent | |
Pollack et al. | Hydrazino-type N 2 S 2 chelators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |